Arbutus Biopharma
ABUS
153 hedge funds and large institutions have $340M invested in Arbutus Biopharma in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 13 closing their positions.
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
34% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 41
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
6% more funds holding
Funds holding: 144 → 153 (+9)
1.37% more ownership
Funds ownership: 53.55% → 54.92% (+1.4%)
2% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $2.35M
13% less capital invested
Capital invested by funds: $389M → $340M (-$48.9M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$3.23M |
| 2 |
JP Morgan Chase
New York
|
+$2.97M |
| 3 |
BlackRock
New York
|
+$2.64M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.28M |
| 5 |
WCM
Whitefort Capital Management
New York
|
+$1.38M |
Top Sellers
| 1 |
FCM
FourWorld Capital Management
New York
|
-$6.42M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.6M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$1.97M |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$1.66M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.21M |
ABUS Hedge Fund Activity: Q4 2024 in Review
153 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2024, worth a combined $340M — down 13% from $389M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ABUS positions and 13 closed out — a net gain of 9 holders — while 55 added to existing stakes and 41 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.23M. The largest seller was FourWorld Capital Management, cutting an estimated $6.42M.
- 153 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2024, up from 144 in Q3 2024.
- Funds reported $340M of Arbutus Biopharma stock for Q4 2024, down 13% quarter-over-quarter.
- 22 funds opened new Arbutus Biopharma positions in Q4 2024 and 13 closed out, a net change of +9 holders.
- The largest Arbutus Biopharma buyer in Q4 2024 was Morgan Stanley, an estimated $3.23M added.
- The largest Arbutus Biopharma seller in Q4 2024 was FourWorld Capital Management, an estimated $6.42M sold.
Based on aggregated 13F filings for Q4 2024.